サクサク読めて、アプリ限定の機能も多数!
トップへ戻る
パリ五輪
primeinc.org
Navigating Endocrine Resistance: Latest Strategies in HR+/HER2- Breast Cancer CareWhile endocrine therapies are widely employed for treating HR+/HER2- breast cancer, many patients with advanced or metastatic disease eventually develop resistance. As the treatment landscape continues to evolve, it is important to stay up to date on key advancements in managing endocrine resistance in this setting.
The Future of NSCLC Care: Leveraging Biomarker Testing in the Management of Early-Stage, Resectable DiseaseJoin us for an engaging discussion on integrating biomarker-directed therapies into early-stage, resectable NSCLC care. We will delve into the latest clinical evidence, as well as real-world data and insights gleaned from community oncology care teams across the US who participated in a quali
このページを最初にブックマークしてみませんか?
『PRIME® Continuing Medical Education』の新着エントリーを見る
j次のブックマーク
k前のブックマーク
lあとで読む
eコメント一覧を開く
oページを開く